AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

New target for development of anti-fibrotic drugs

Summary: Monash University researchers have identified and validated a novel anti-fibrosis target - IRAP. Inhibition of this target with the proprietary small molecule lead series completely reversed cardiac and renal fibrosis in clinically relevant disease models. We nows eek a partner to develop novel lead candidate inhibitors as safe and effective anti-fibrotic drugs.

Technology Benefits: - Potential to develop ‘Best in Disease’
anti-fibrotic drugs that reverse existing
fibrotic lesions
- ‘Proof of Mechanism’ with in vivo
efficacy for small molecule inhibitors
- Differentiated and vasoprotective
mechanism of action

Technology Application: Anti-fibrotic therapeutic to reverse existing lesions.

Detailed Technology Description: Researchers from the Monash BioMedicine Discovery Institute (A/Prof. Siew Chai, Prof. Rob Widdop & Dr. Tracey Gaspari) and Monash Institute of Pharmaceutical Sciences (A/Prof. Phil Thompson) have identified IRAP as a new target for the treatment of cardiac, kidney, liver and potentially other organ fibrosis. IRAP is an extracellular protein that is ‘druggable’ with small molecule inhibitors. A compelling body of evidence supporting proof-of-mechanism and validation with a lead series has shown that IRAP inhibition can prevent and reverse fibrosis.
- IRAP deficiency/inhibition protects against the development of cardiac and renal fibrosis in aged mice and cardiac fibrosis in Ang II-treated mice.
- IRAP inhibition completely reverses cardiac fibrosis in aged mice, with corresponding decreases in inflammatory and oxidative stress markers and increases in NO bioavailability.
- IRAP deficiency/inhibition protects against ischemia-reperfusion damage and improves function of aged ischemic hearts.
- IRAP inhibition protects and reverses age mediated renal fibrosis and high salt induced cardiac/renal fibrosis

Type of Cooperation: Licensing

Application Date: 29/07/2016 00:00:00

Application No.: AU2016301113
JA2018-504650
Others

Others: Monash seeks a partner to optimise the lead series and develop new drug candidates against this exciting target.

ID No.: 2015-027

Country/Region: Australia

For more information, please click Here